Open Label, Dose Escalation Phase I Study of AZD2281
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and tolerability of AZD2281 following single
and multiple oral doses in patients in Japan with advanced solid malignancies